Skip to content
Search

Latest Stories

Submit Guest Post

UK issues recall of antidepressant tablets after packaging error

The action follows a patient complaint after a sealed carton of sertraline was found to contain one blister strip of Citalopram 40mg tablets.

​Amarox

Amarox Limited said it is recalling one batch of Sertraline 100mg film-coated tablets as a precaution.

MHRA

A BATCH of antidepressant medication in the UK has been recalled after a packaging error led to the wrong tablets being included in some packs.

Amarox Limited said it is recalling one batch of Sertraline 100mg film-coated tablets as a precaution.


The action follows a patient complaint after a sealed carton of sertraline was found to contain one blister strip of Citalopram 40mg tablets.

Sertraline and citalopram are both selective serotonin reuptake inhibitors used to treat depression, anxiety disorders and related conditions by increasing serotonin levels in the brain. Both medicines are produced by the same manufacturer at the same site. The issue has been linked to an error during the packaging of blister strips into cartons.

Patients in the UK who may have taken Citalopram 40mg tablets by mistake or are experiencing side effects have been advised to seek medical advice.

Dr Alison Cave, MHRA Chief Safety Officer, said: “If you have been prescribed Sertraline 100mg tablets and have received batch number V2500425, please check the carton contains the right medication. You can find the batch number and expiry date printed on the side of the outer packaging.

“If the blister strips inside the carton are labelled Citalopram 40mg, please contact your pharmacy as soon as possible. If they are labelled Sertraline 100mg, no further action is needed.”

“Patients who have accidentally taken citalopram instead of - or as well as - sertraline may experience some heightened serotonergic side effects. These can include nausea, headache, sleep changes and mild anxiety.”

Pharmacists and other healthcare professionals have been asked to contact affected patients and return any remaining stock. The MHRA has also advised stopping supply of the affected batch and returning it to suppliers. Suspected adverse reactions should be reported through the MHRA Yellow Card scheme.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

NHS anti-racism efforts fail to deliver as Asian, ethnic minority managers face career barriers: Report

Highlights:

  • 1 in 5 BAME NHS managers surveyed plan to leave within three years.
  • Almost 80 per cent reported racism, exclusion or barriers to career progression.
  • 28.6 per cent, 434,077 people — of NHS trust staff were from BME backgrounds in March 2024.
  • Only 48.8 per cent of BME staff said they had equal opportunities for career progression, versus 59.4 per cent of white staff.
  • Just 12.7 per cent of very senior NHS managers were from BME backgrounds, compared with 28.6 per cent of the overall NHS trust workforce.

  • The NHS could be facing a loss of experienced British Asian and other minority ethnic managers, with one in five managers surveyed saying they plan to leave the health service within the next three years.

    Keep ReadingShow less